世界の胃がん・胃がん治療市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20SP05297)
◆英語タイトル:Global Stomach Cancer and Gastric Cancer Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20SP05297
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年9月23日(※2024年版があります。お問い合わせください。)
◆ページ数:105
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、胃がん・胃がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。胃がん・胃がん治療の種類別市場規模(プログラム細胞死タンパク質1(PD-1)阻害剤、ヒト上皮成長因子受容体(HER2)拮抗薬、血管内皮増殖因子受容体(VEGFR)拮抗薬、その他)、用途別市場規模(病院、クリニック)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Ipsen Pharma、Celltrion Inc.、Eli Lilly、Merck & Co., Inc.、Bayer AG、Bristol-Myers Squibb Company、Jiangsu Hengrui Medicine Co., Ltd.、Novartis AG、Roche、TAIHO PHARMACEUTICAL CO., LTD.
・地域別グローバル市場分析 2015年-2020年
・胃がん・胃がん治療の北米市場(アメリカ、カナダ、メキシコ)
・胃がん・胃がん治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・胃がん・胃がん治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・胃がん・胃がん治療の南米市場(ブラジル、アルゼンチン)
・胃がん・胃がん治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:プログラム細胞死タンパク質1(PD-1)阻害剤、ヒト上皮成長因子受容体(HER2)拮抗薬、血管内皮増殖因子受容体(VEGFR)拮抗薬、その他
・用途別分析:病院、クリニック
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The Stomach Cancer and Gastric Cancer Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Stomach Cancer and Gastric Cancer Treatment sales will be xx in 2020 from Stomach Cancer and Gastric Cancer Treatment million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Stomach Cancer and Gastric Cancer Treatment market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Stomach Cancer and Gastric Cancer Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Stomach Cancer and Gastric Cancer Treatment and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Stomach Cancer and Gastric Cancer Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Stomach Cancer and Gastric Cancer Treatment market has been segmented into:
Programmed Cell Death Protein 1 (PD-1) Inhibitors
Human Epidermal Growth Factor Receptor (HER2) Antagonists
Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
Others

By Application, Stomach Cancer and Gastric Cancer Treatment has been segmented into:
Hospitals
Clinics

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Stomach Cancer and Gastric Cancer Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Stomach Cancer and Gastric Cancer Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Stomach Cancer and Gastric Cancer Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Stomach Cancer and Gastric Cancer Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Stomach Cancer and Gastric Cancer Treatment Market Share Analysis
Stomach Cancer and Gastric Cancer Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Stomach Cancer and Gastric Cancer Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Stomach Cancer and Gastric Cancer Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Stomach Cancer and Gastric Cancer Treatment are:
Ipsen Pharma
Celltrion Inc.
Eli Lilly
Merck & Co., Inc.
Bayer AG
Bristol-Myers Squibb Company
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Roche
TAIHO PHARMACEUTICAL CO., LTD.
Among other players domestic and global, Stomach Cancer and Gastric Cancer Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

【レポートの目次】

1 Stomach Cancer and Gastric Cancer Treatment Market Overview
1.1 Product Overview and Scope of Stomach Cancer and Gastric Cancer Treatment
1.2 Classification of Stomach Cancer and Gastric Cancer Treatment by Type
1.2.1 Global Stomach Cancer and Gastric Cancer Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Stomach Cancer and Gastric Cancer Treatment Revenue Market Share by Type in 2019
1.2.3 Programmed Cell Death Protein 1 (PD-1) Inhibitors
1.2.4 Human Epidermal Growth Factor Receptor (HER2) Antagonists
1.2.5 Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
1.2.6 Others
1.3 Global Stomach Cancer and Gastric Cancer Treatment Market by Application
1.3.1 Overview: Global Stomach Cancer and Gastric Cancer Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Stomach Cancer and Gastric Cancer Treatment Market by Regions
1.4.1 Global Stomach Cancer and Gastric Cancer Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Stomach Cancer and Gastric Cancer Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Stomach Cancer and Gastric Cancer Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Stomach Cancer and Gastric Cancer Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Stomach Cancer and Gastric Cancer Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Stomach Cancer and Gastric Cancer Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Stomach Cancer and Gastric Cancer Treatment Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Stomach Cancer and Gastric Cancer Treatment Industry Impact
1.5.1 COVID-19 Potential Implications for the Stomach Cancer and Gastric Cancer Treatment
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Stomach Cancer and Gastric Cancer Treatment
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Ipsen Pharma
2.1.1 Ipsen Pharma Details
2.1.2 Ipsen Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Ipsen Pharma SWOT Analysis
2.1.4 Ipsen Pharma Product and Services
2.1.5 Ipsen Pharma Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Celltrion Inc.
2.2.1 Celltrion Inc. Details
2.2.2 Celltrion Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Celltrion Inc. SWOT Analysis
2.2.4 Celltrion Inc. Product and Services
2.2.5 Celltrion Inc. Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Eli Lilly SWOT Analysis
2.3.4 Eli Lilly Product and Services
2.3.5 Eli Lilly Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Merck & Co., Inc.
2.4.1 Merck & Co., Inc. Details
2.4.2 Merck & Co., Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Merck & Co., Inc. SWOT Analysis
2.4.4 Merck & Co., Inc. Product and Services
2.4.5 Merck & Co., Inc. Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bayer AG
2.5.1 Bayer AG Details
2.5.2 Bayer AG Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bayer AG SWOT Analysis
2.5.4 Bayer AG Product and Services
2.5.5 Bayer AG Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bristol-Myers Squibb Company
2.6.1 Bristol-Myers Squibb Company Details
2.6.2 Bristol-Myers Squibb Company Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bristol-Myers Squibb Company SWOT Analysis
2.6.4 Bristol-Myers Squibb Company Product and Services
2.6.5 Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Jiangsu Hengrui Medicine Co., Ltd.
2.7.1 Jiangsu Hengrui Medicine Co., Ltd. Details
2.7.2 Jiangsu Hengrui Medicine Co., Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Jiangsu Hengrui Medicine Co., Ltd. SWOT Analysis
2.7.4 Jiangsu Hengrui Medicine Co., Ltd. Product and Services
2.7.5 Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis AG
2.8.1 Novartis AG Details
2.8.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Novartis AG SWOT Analysis
2.8.4 Novartis AG Product and Services
2.8.5 Novartis AG Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Roche SWOT Analysis
2.9.4 Roche Product and Services
2.9.5 Roche Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 TAIHO PHARMACEUTICAL CO., LTD.
2.10.1 TAIHO PHARMACEUTICAL CO., LTD. Details
2.10.2 TAIHO PHARMACEUTICAL CO., LTD. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 TAIHO PHARMACEUTICAL CO., LTD. SWOT Analysis
2.10.4 TAIHO PHARMACEUTICAL CO., LTD. Product and Services
2.10.5 TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Stomach Cancer and Gastric Cancer Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Stomach Cancer and Gastric Cancer Treatment Players Market Share
3.2.2 Top 10 Stomach Cancer and Gastric Cancer Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Stomach Cancer and Gastric Cancer Treatment Revenue and Market Share by Regions
4.2 North America Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
5 North America Stomach Cancer and Gastric Cancer Treatment Revenue by Countries
5.1 North America Stomach Cancer and Gastric Cancer Treatment Revenue by Countries (2015-2020)
5.2 USA Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
6 Europe Stomach Cancer and Gastric Cancer Treatment Revenue by Countries
6.1 Europe Stomach Cancer and Gastric Cancer Treatment Revenue by Countries (2015-2020)
6.2 Germany Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
6.4 France Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Stomach Cancer and Gastric Cancer Treatment Revenue by Countries
7.1 Asia-Pacific Stomach Cancer and Gastric Cancer Treatment Revenue by Countries (2015-2020)
7.2 China Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
7.5 India Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
8 South America Stomach Cancer and Gastric Cancer Treatment Revenue by Countries
8.1 South America Stomach Cancer and Gastric Cancer Treatment Revenue by Countries (2015-2020)
8.2 Brazil Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Stomach Cancer and Gastric Cancer Treatment by Countries
9.1 Middle East & Africa Stomach Cancer and Gastric Cancer Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Stomach Cancer and Gastric Cancer Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Stomach Cancer and Gastric Cancer Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Stomach Cancer and Gastric Cancer Treatment Market Forecast by Type (2019-2024)
10.3 Programmed Cell Death Protein 1 (PD-1) Inhibitors Revenue Growth Rate (2015-2025)
10.4 Human Epidermal Growth Factor Receptor (HER2) Antagonists Revenue Growth Rate (2015-2025)
10.5 Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists Revenue Growth Rate (2015-2025)
10.6 Others Revenue Growth Rate (2015-2025)
11 Global Stomach Cancer and Gastric Cancer Treatment Market Segment by Application
11.1 Global Stomach Cancer and Gastric Cancer Treatment Revenue Market Share by Application (2015-2020)
11.2 Stomach Cancer and Gastric Cancer Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
12 Global Stomach Cancer and Gastric Cancer Treatment Market Size Forecast (2021-2025)
12.1 Global Stomach Cancer and Gastric Cancer Treatment Market Size Forecast (2021-2025)
12.2 Global Stomach Cancer and Gastric Cancer Treatment Market Forecast by Regions (2021-2025)
12.3 North America Stomach Cancer and Gastric Cancer Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Stomach Cancer and Gastric Cancer Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Stomach Cancer and Gastric Cancer Treatment Revenue Market Forecast (2021-2025)
12.6 South America Stomach Cancer and Gastric Cancer Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Stomach Cancer and Gastric Cancer Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Ipsen Pharma、Celltrion Inc.、Eli Lilly、Merck & Co., Inc.、Bayer AG、Bristol-Myers Squibb Company、Jiangsu Hengrui Medicine Co., Ltd.、Novartis AG、Roche、TAIHO PHARMACEUTICAL CO., LTD.

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の胃がん・胃がん治療市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Stomach Cancer and Gastric Cancer Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。